Loading…
CGBIO announced an agreement with LifeHealthcare to supply its rhBMP-2 bone graft product NOVOSIS for the Australian and New Zealand markets, with potential revenue of KRW 200 billion.
K2M Group Holdings and LifeHealthcare Group Limited entered into a new five-year supply agreement for the distribution of K2M's spinal technologies in Australia and New Zealand.